1Belghiti J, Fuks D. Liver resection and transplantation inhepatocellular carcinoma[J], Liver Cancer,2012,1(2) :71-82. 被引量：1
2Dhanasekaran R,Limaye A,Cabrera R. Hepatocellularcarcinoma : current trends in worldwide epidemiology.risk factors, diagnosis, and therapeutics [J]. Hepat Med,2012,4:19-37. 被引量：1
3Kudo M. Targeted therapy for liver cancer: updated re-view in 2012[J]. Curr Cancer Drug Targets,2012,12(9):1062-1072. 被引量：1
4Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet,2012,379(9822):1245-1255. 被引量：1
5Forner A, Bruix J. East meets the West-portal pressurepredicts outcome of surgical resection for hepatocellularcarcinoma [ J]. Nat Clin Pract Gastroenterol Hepatol,2009,6(1):14-15. 被引量：1
7Poon RT. Prevention of recurrence after resection of hep-atocellular carcinoma:a daunting challenge[J]. Hepatolo-gy,2011,54(3):757-759. 被引量：1
8Alsina AE. Nakshabandi A. Makris AM, et al. Liver trans-plantation for hepatocellular carcinoma in Puerto Ricans : un-derutilization of a curative therapy [J]. P R Health Sci J,2014,33(3):170-176. 被引量：1
9Llovet JM, Ricci S,Mazzaferro V, et al. Sorafenib. in ad-vanced hepatocellular carcinoma[J], N Engl J Med,2008. 被引量：1
10Di Marco V,De Vita F,Koskinas J, et al. Sorafenib: from literature to clinical practice. Annals of oncology: official journal of-the European Societ[J]. Ann Oncol, 2013,24 Suppl 2 : ii30-37. 被引量：1
